A case of ovulatory cycle-dependent symptoms in woman with previous interferon beta therapy.
A woman with a menstrual cycle-dependent fever (more than 38 degrees C) and severe fatigue that disrupted her ability to work was referred to our hospital. Six years ago, the patient received interferon beta injections (6,000,000 IU day-1x48 days) for the treatment of hepatitis C virus. Although the treatment was successful against the virus, the symptomatic fever occurred monthly since the third year after receiving the treatment. The symptoms occurred a few days after ovulation in every menstrual cycle. When the ovarian function was suppressed by GnRH agonist (GnRHa), the symptoms disappeared. While in anovulation, the patient received estrogen followed by estrogen with progestogen, which resembles the sex hormone milieu of a normal menstrual cycle without the LH surge; this treatment did not induce the symptoms. When human CG (hCG) was injected on the beginning day of estrogen with progestogen following treatment with estrogen alone, the previous symptoms reappeared. However, the hCG injection without estrogen priming did not induce the symptoms. These studies indicated that the LH surge after estrogen priming induced the symptoms. Changes in serum inflammatory cytokine levels (interleukin-1, interleukin-6, and tumor necrosis factor-alpha) were examined during the ovulatory cycle and the interleukin-1 levels during the treatment. There were no significant changes on these levels in the febrile period. The patient experienced normal menstrual cycles after finishing the five-month GnRHa treatment. Although her symptoms still occur, they are mild and do not require further medical treatment.
Nakamura
Yasuhiko
Y
Department of Reproductive, Pediatric and Infectious Science, Yamaguchi University School of Medicine, Ube, Japan.
Hino
Keisuke
K
D000328:Adult; D000858:Anovulation / Q000139:chemically induced; D016207:Cytokines / Q000097:blood; D005221:Fatigue / Q000139:chemically induced / Q000209:etiology*; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000209:etiology*; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects* / Q000378:metabolism
D016207:Cytokines; D016899:Interferon-beta; D007986:Luteinizing Hormone